A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their presentation, Redeye analyst Oscar Bergman moderated a Q&A session.
IDL Diagnostics and concile at WHX Labs Dubai
Last week, IDL Diagnostics participated as an exhibitor at WHX Labs Dubai together with concile as part of the recently announced joint venture. The main focus is on delivering multiple biomarkers across different POC reader configurations and supporting infection,...
